Susan Franks
Plus aucun poste en cours
Profil
Susan Franks, former Vice President- Global Regulatory Affairs at Teva Pharmaceuticals USA, Inc., and Senior Vice President & Head-Regulatory Affairs at Braeburn, Inc., has also served as Senior Vice President & Head-Regulatory Affairs at Eliem Therapeutics, Inc. from 2022 to 2023.
She holds an undergraduate degree from Clarkson University and a graduate degree from Lehigh University.
Anciens postes connus de Susan Franks
| Sociétés | Poste | Fin |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | General Counsel | 01/04/2023 |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | General Counsel | - |
| BRAEBURN INC. | General Counsel | - |
Formation de Susan Franks
| Clarkson University | Undergraduate Degree |
| Lehigh University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | Health Technology |
Braeburn, Inc.
 Braeburn, Inc. Miscellaneous Commercial ServicesCommercial Services Braeburn, Inc. manufactures pharmaceutical products. It focuses on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain and schizophrenia. The firm develops Probuphine for the treatment of adult patients with opioid dependence. The company was founded in 2012 and is headquartered in Princeton, NJ. | Commercial Services |
